Translational Breast Cancer Research Consortium

• NCT07340541

  Collaborator, Phase 2, Recruiting, 700 people, 14 Jan 2026

• NCT06439693

  Collaborator, Phase 2, Recruiting, 72 people, 3 Jun 2024

• NCT05501704

  Collaborator, Phase 2, Recruiting, 60 people, 15 Aug 2022

• Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

  Collaborator, Phase 2, Active, not recruiting, 96 people, 12 Apr 2021

• NCT04443348

  Collaborator, Phase 2, Active, not recruiting, 120 people, 23 Jun 2020

• NCT03095352

  Collaborator, Phase 2, Completed, 76 people, 29 Mar 2017

• Ruxolitinib for Premalignant Breast Disease

  Collaborator, Phase 2, Completed, 84 people, 10 Oct 2016

• NCT02384239

  Collaborator, Phase 2, Completed, 70 people, 10 Mar 2015

• NCT01982448

  Collaborator, Phase 2, Completed, 147 people, 13 Nov 2013

• NCT01937117

  Collaborator, Phase 2, Active, not recruiting, 88 people, 9 Sept 2013

• NCT00999804

  Collaborator, Phase 2, Active, not recruiting, 128 people, 22 Oct 2009

• NCT00925652

  Collaborator, Phase 2, Terminated, 55 people, 22 Jun 2009

• NCT00577122

  Collaborator, Phase 2, Completed, 30 people, 19 Dec 2007

Sources: clinicaltrials.gov